Ticker: ESPR
Sector: Healthcare
Performance so far this year: +187.65%
Price target: $52.00
Implied upside potential: 46%
UBS says: "Esperion is a top pick as we believe the company is strategically well-positioned with a novel lipid-lowering oral agent that has been de-risked from a clinical and regulatory perspective, offering investors a highly attractive risk-reward profile."
Click here for a real-time Esperion Therapeutics Inc. chart.